신라젠

215600KOSDAQ자연과학 및 공학 연구개발업

52.5 / 100

Reference Date: 2026-07-24

Financial Score21.0 / 40

News Sentiment17.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Declined 13.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Shinara Gen is a biotech venture company established in 2006, focusing on developing anti-cancer drugs. The company specializes in oncolytic virus therapies, mitotic checkpoint inhibitors, and generic pharmaceuticals. Its oncolytic viruses selectively target cancer cells and are being studied in combination therapies with immune checkpoint inhibitors.

Number of Employees

56people

Average Salary

82.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

2.62Industry Average 2.522.5Point

Higher than industry avg (caution)

ROE

-20.00Industry Average -32.093.5Point

Below industry avg

Debt Ratio

1.50Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲67.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼10.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.0% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 4Neutral 3Negative 0Average Sentiment Score 70

Neutral
정통망법 개정 속 김어준 유튜브 일부 영상 국내 차단
Neutral
김어준 유튜브 영상 일부 차단…‘명예훼손 신고’로 철퇴
김어준 유튜브 영상 일부 차단은 관련 법률 개정에 따른 결과로, 신라젠과 직접적인 연관성이 없다.
Positive
비원메디슨, 혈액암서 '캐모프리' 승부수…신라젠과 파트너십 확대 가.....
신라젠과의 파트너십 확대 가능성으로 신라젠 주가에 긍정적 영향 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 2,080Won52-week high 4,97552-week low 1,996

1-month return1.0Point

1m -13.87% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0